Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma
NCT00004188Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2001
- Primary completion
- Oct 2007
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of peripheral blood stem cells in neuroblastoma and ganglioneuroblastoma (GNB) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-Free Survival up to 6 years and Rate of occurrence of toxic (non disease-related) deaths. Started Feb 2001; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT00004188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004188.